Used in the treatment of various cancers by blocking the PD-L1 protein, which helps cancer cells evade the immune system. By inhibiting this pathway, the antibody enhances the body's T-cell response against tumor cells. It is primarily investigated in solid tumors such as non-small cell lung cancer, melanoma, and bladder cancer. The antibody enables the immune system to recognize and destroy cancer cells more effectively, often used in combination with other immunotherapies or chemotherapies. Its application is key in advancing personalized cancer treatments, especially in patients whose tumors express high levels of PD-L1.